

GENERAL INFORMATION

ORGANISING SECRETARIAT

European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - 20133 Milan – Italy
Fax +39 0223902531 – www.eso.net
Email: raretumours@eso.net

VENUE

Fondazione Cariplo Conference Center
Via Romagnosi, 8
Milan, Italy
www.centrocongressifondazionecriplo.it

REGISTRATION

Register online at www.eso.net

	Early (by 31 October)	Late (from 1 November)
Registration fees	EUR 200	EUR 250
Club ESO members	EUR 150	EUR 250
ESMO members	EUR 150	EUR 250

Rates are quoted in Euro and include VAT.

Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.

TRAVEL GRANTS

Travel grants are made available on a competitive basis thanks to the support of Rare Cancers Europe. Priority will be given to younger candidates and low/middle income Countries. To submit the Travel Grant application please complete the online form and upload your Curriculum vitae and motivation letter by 1st October. All applicants will be contacted by 15th October. Unselected applicants will still be able to register with the early rate fee (deadline: 31st October).

Participants coming from:

Italy	€ 500 (plus free registration)
Southern and Western Europe	€ 700 (plus free registration)
Northern, Central and Eastern Europe	€ 800 (plus free registration)
Other and overseas	€ 1000 (plus free registration)

IMPORTANT DEADLINES
TRAVEL GRANTS: **1 October 2017**
EARLY REGISTRATION: **31 October 2017**
LATE REGISTRATION: **from 1 November 2017**

ACCREDITATION

Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system. EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). Information on the status of the applications can be obtained from the organising Secretariat.

CANCELLATION OF REGISTRATION OR REPLACEMENT

Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 80 will be refunded after the event, provided that the cancellation is received by ESO before 2 November. Replacements will be possible till 2 November.

BADGE

The badge is the only official evidence of registration and should be worn at all times during the event.

INSURANCE

The organisers bear no responsibility for untoward events in relation to the participation in the Course. Participants are advised to take out their own personal and travel insurance.

OFFICIAL LANGUAGE

The official language will be English. No translation will be provided.

ACKNOWLEDGEMENT

ESO wishes to express its gratitude to
Fondazione Cariplo - Iniziative Patrimoniali S.p.A.
for their support in hosting the course in its premises



ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

35
years

ES
European
School
of
Oncology
LEARNING TO CARE

R
CANCERS
EUROPE
E

2ND ESO-ESMO-RCE CLINICAL UPDATE ON RARE ADULT SOLID CANCERS

2-4 December 2017
Milan, Italy

Chairs:

J.Y. Blay, FR

P.G. Casali, IT

R. Stahel, CH

Held in collaboration with

 **Fondazione IRCCS
Istituto Nazionale dei Tumori**

Sistema Socio Sanitario

 **Regione
Lombardia**

In the framework of



**European
Reference
Network**

for rare or low prevalence
complex diseases

 **Network
Adult Cancers
(ERN EURACAN)**

JARC
Joint Action on Rare Cancers

INTRODUCTION

Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while rare adult solid cancers are hardly grouped together and approached as a collective group of neoplasms. Indeed, they account for as many as 15% of all new cancer cases, thus being the main group within rare cancers. This Course is aimed at dealing with them on an annual basis, to provide the community of clinical oncologists specialising in these tumors with a regular update of recent advances in this specific area. The ultimate goal is to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence.

According to the RARECARE project, which provided a definition and a list of rare cancers, rare adult solid cancers include the following big families of tumors, each of them being therefore covered by a corresponding educational session within this Course:

- Rare skin cancers & non-cutaneous melanoma
- Rare thoracic tumors
- Rare female genital cancers
- Neuroendocrine tumors
- Endocrine gland tumors
- Sarcomas
- Digestive rare cancers
- Rare urological and male genital tumors
- Central nervous system neoplasms
- Head & neck cancers

Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment.

This year we are amid the process of creation of the new European Reference Networks (ERN) on rare diseases, including rare adult solid cancers, with the ERN named EURACAN. Many speakers and moderators will thus come from EURACAN and definitely will be happy to meet Oncologists working within it or in collaboration with it.

From the educational point of view, one cannot expect that even experienced clinical oncologists are knowledgeable about all these tumors. For this reason, the European Faculty of this Course is asked to focus on most recent advances always trying to put them into the context of state-of-the-art treatment of these tumors, with a special view to ESMO Clinical Practice Guidelines.

PROGRAMME

Saturday, 2 December 2017

9:00 Registration and coffee entry

INTRODUCTION (Plenary session*)

Moderators: J.Y. Blay, FR - P.G. Casali, IT - R. Stahel, CH

9:45 Welcome from ESO and ESMO

F. Peccatori, IT - R. Stahel, CH

10:00 The problem of rare cancers

P.G. Casali, IT

10:15 The epidemiology of rare cancers

A. Trama, IT

10:30 The pathologic diagnosis in rare cancers

A.P. Dei Tos, IT

10:45 The European Reference Networks

J.Y. Blay, FR

11:00 Discussion

PATIENT EMPOWERMENT IN RARE CANCERS (Plenary session *)

Moderators: F. De Lorenzo, BE - M. Wartenberg, DE

11:30 Patient empowerment in rare cancers: a consensus

G. Pravettoni, IT

11:45 The EU scenario

F. De Lorenzo, BE

12:00 Patient advocacy on rare cancers as a resource

M. Wartenberg, DE

12:15 Patient involvement in clinical trials

K. Oliver, UK

12:30 Discussion

13:00 Lunch

RARE THORACIC CANCERS

Moderators: M. Garassino, IT - R. Stahel, CH

14:00 The epidemiology of mesothelioma

A. Trama, IT

14:15 Mesothelioma

R. Stahel, CH

14:30 Thymic tumors

M. Garassino, IT

14:45 Discussion

NEUROENDOCRINE TUMORS

Moderators: D. Talbot, UK - F. De Braud, IT

15:15 Thoracic neuroendocrine tumors

D. Talbot, UK

15:30 Gastroenteropancreatic neuroendocrine tumors

N. Fazio, IT

15:45 Surgery in neuroendocrine tumors

V. Mazzaferro, IT

16:00 Discussion

16:30 Coffee break

DIGESTIVE RARE CANCERS

Moderators: V. Mazzaferro, IT - L. Wyrwicz, PL

17:00 Biliary tumors

F. De Braud, IT

17:15 Anal carcinoma

R. Glynne-Jones, UK

17:30 Peritoneal mesothelioma & pseudomyxoma

M. Deraco, IT

17:45 Discussion

Sunday, 3 December 2017

CNS TUMORS

Moderators: R. Soffietti, IT - M. van den Bent, NL

8:30 The frontiers of neurosurgery of brain tumors

J.C. Tonn, DE

8:45 The frontiers of radiation therapy of brain tumors

S. Villà, ES

9:00 Gliomas: state-of-the-art approach

M. van den Bent, NL

9:15 Precision medicine in brain tumors

R. Soffietti, IT

9:30 Discussion

10:00 Coffee break

SARCOMAS

Moderators: P.G. Casali, IT - A. Gronchi, IT

10:30 The variegated pathology of sarcomas

A.P. Dei Tos, IT

- 10:45** The surgical margin in sarcomas
- 11:00** Medical therapy of adult soft tissue sarcomas
- 11:15** Medical therapy of GIST
- 11:30** Ewing sarcoma
- 11:45** Osteosarcoma
- 12:00** "Rare" sarcomas
- 12:15** Histiocytic/dendritic cell neoplasms
- 12:30** Discussion
- 13:00** Lunch

A. Gronchi, IT
 P.G. Casali, IT
 J.Y. Blay, FR
 S. Ferrari, IT
 S. Bielack, DE
 S. Stacchiotti, IT
 A.M. Frezza, IT

RARE FEMALE GENITAL CANCERS

Moderators: F. Raspagliesi, IT - M. Seckl, UK

- 14:00** Vulvar and vaginal cancers
- 14:15** Rare endometrial cancers
- 14:30** Uterine sarcomas
- 14:45** Non-epithelial ovarian tumors
- 15:00** Trophoblastic tumors
- 15:15** Discussion
- 15:45** Coffee break

F. Raspagliesi, IT
 D. Lorusso, IT
 P.G. Casali, IT
 I. Ray-Coquard, FR
 M. Seckl, UK

RARE UROGENITAL CANCERS

Moderators: J.A. Gietema, NL - N. Nicolai, IT

- 16:15** Testicular cancer
- 16:30** Penile cancers
- 16:45** Discussion

A. Necchi, IT
 J.A. Gietema, NL

RARE SKIN TUMORS & UVEAL MELANOMA

Moderators: M. Angi, IT - C. Lebbé, FR

- 17:15** The integrated approach to uveal melanoma
- 17:30** Merkel cell carcinoma
- 17:45** Skin adnexal tumors
- 18:00** Discussion

M. Angi, IT
 C. Lebbé, FR
 L. Licitra, IT

Monday, 4 December 2017

HEAD & NECK CANCERS

Moderators: V. Gregoire, BE - L. Licitra, IT

- 8:30** Natural history of H&N cancers
- 8:45** The potential of radiation therapy for H&N cancers
- 9:00** Surgery in H&N cancers and its innovations
- 9:15** Laryngeal & hypopharyngeal carcinoma
- 9:30** Oropharyngeal carcinoma
- 9:45** Nasopharyngeal carcinoma
- 10:00** Oral cavity tumors
- 10:15** Salivary gland tumors
- 10:30** Discussion
- 11:00** Coffee break

C. Simon, CH
 V. Gregoire, BE
 C. Piazza, IT
 L. Licitra, IT
 V. Gregoire, BE
 L. Licitra, IT
 C. Simon, CH
 L. Licitra, IT

ENDOCRINE GLAND TUMORS

Moderators: S. Leboulleux, FR - L. Licitra, IT

- 11:30** Adrenal cancer
- 11:45** Thyroid cancer
- 12:00** Anaplastic thyroid carcinoma
- 12:15** Discussion
- 12:45** Closing remarks, with a view to networking...

S. Grisanti, IT
 S. Leboulleux, FR
 C. De La Fouchardière, FR
 P.G. Casali, IT (Plenary*)

*Linked to Rare Cancer Patient Advocates pilot training course

FACULTY

- M. Angi**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y Blay, Centre Léon Bérard, Lyon, FR
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSSg, Treviso, IT
C. De La Fouchardière, Centre Léon Bérard, Lyon FR
F. De Lorenzo, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
S. Ferrari, Istituti Ortopedici Rizzoli, Bologna, IT
A.M. Frezza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.A. Gietema, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
V. Gregoire, Université Catholique, Louvain, BE
S. Grisanti, A.O. Spedali Civili, Brescia, IT
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
C. Lebbé, Hopital St. Louis, Paris, FR
S. Leboulleux, Institut Gustave Roussy, Villejuif, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
D. Lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
V. Mazzaferro, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Necchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Oliver, International Brain Tumour Alliance, Tadworth, UK
F. Peccatori, European School of Oncology, Milan, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
G. Pravettoni, Istituto Europeo di Oncologia, Milan, IT
F. Raspagliesi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
M. Seckl, Hammersmith Campus, London, UK
C. Simon, Université de Lausanne, CHUV Lausanne, CH
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
D. Talbot, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
J.C. Tonn, University of Munich, Munich, DE
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Van den Bent, Erasmus MC Cancer Institute, Rotterdam, NL
S. Villà, Hospital Universitari Germans Trias i Pujol, Badalona, ES
M. Wartenberg, Sarcoma Patients EuroNet, Wölfersheim, DE
L. Wyrwicz, Curie Institute of Oncology, Warsaw, PL

2ND ESO-ESMO-RCE CLINICAL UPDATE ON RARE ADULT SOLID CANCERS

2-4 December 2017, Milan, Italy

Please fill in this form in BLOCK CAPITALS and send by the deadline to:

European School of Oncology - Via Turati 29 - 20121 Milan - Italy

Fax: +39 02 85464545 - E mail: raretumours@eso.net

ONLINE REGISTRATION AT WWW.ESO.NET

PARTICIPANT'S DETAILS

Dr. Prof. Mrs. Mr.

Surname Name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Profession

Specialisation Main field

VAT number (*compulsory for self-employed persons*)

Fiscal code (*Italian residents only*)

Are you an ESMO Member? YES NO

If YES: Membership ID: Expire date (DD/MM/YYYY):

If your invoice details are different to those above, please complete the following section:

Invoice contact person

Address

Phone email

VAT number (*compulsory for self-employed persons*)

Fiscal Code (*Italian residents only*)

REGISTRATION FEES:

Rates are quoted in Euro and include VAT.

	Early (by 31 October 2017)	Late (from 1 November 2017)
Registration fee	<input type="checkbox"/> EUR 200	<input type="checkbox"/> EUR 250
Club ESO Members	<input type="checkbox"/> EUR 150	<input type="checkbox"/> EUR 250
ESMO Members	<input type="checkbox"/> EUR 150	<input type="checkbox"/> EUR 250

PAYMENT DETAILS:

The registration is processed when payment accompanies the form

(*credit card details or copy of bank transfer*)

Visa/Mastercard Card Number / / /

Expire date / CV2 code

Holder's name: and signature

BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer):

Bank: Banca Popolare di Milano, Agenzia 24 - Milan, Italy

Account holder: European School of Oncology

Number: No. 16333

IBAN: IT96G0558401624 0000000 16333 - **BIC:** BPMIITMMXXX

Reference: "Rare Tumours" + participant's name

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date